72 / 154
S42
A B S T R A C T S
(p=0.2132). Mean (SD) number of days between two visits was
16.55 (9.39) days and 20.83 (17.61) days for bevacizumab- and
conventional chemotherapy respectively.
Table 1 (abstract P010)– Patient demographics at baseline
Chemotherapy +
Chemotherapy
bevazicumab
only
(N=128)
(N=124)
Mean age, years
76.9
78.0
Sex
Male
65%
58%
Female
35%
42%
Chemotherapy treatment
CAPOX – FOLFOX
41 (32.0%)
41 (33.1%)
FOLFIRI
85 (66.4%)
46 (37.1%)
5FU/LV–CAP
2 (1.6%)
37 (29.8%)
ECOG
N=125
N=122
0
61 (48.8%)
52 (42.6%)
1
48 (38.4%)
50 (41.0%)
2
16 (12.8%)
20 (16.4%)
Ongoing medication at baseline
<5
74 (57.8%)
57 (46.0%)
5
54 (42.2%)
67 (54.0%)
Table 2 (abstract P010) – All grade adverse events of interest to
bevacizumab.
Chemotherapy +
Chemotherapy
bevazicumab
only
(N=128)
(N=124)
Arterial thrombotic events
3 (2.3%)
2 (1.6%)
Venous thrombotic events
18 (14.1%)
9 (7.3%)
Epistaxis
21 (16.4%)
11 (8.9%)
Hypertension
17 (13.3%)
10 (8.1%)
Gastrointestinal bleeding
7 (5.5%)
5 (4.0%)
Proteinuria
6 (4.7%)
2 (1.6%)
Conclusion:
In this real life setting, the observed median
treatment duration of bevacizumab containing chemotherapy
was comparable to data found for elderly patients included
in other observational studies. In this group of elderly
patients, the observed safety profile was consistent with
the established safety profile of bevacizumab in prospective
randomized clinical trials and observational registry studies
in the global mCRC population.
Disclosure of interest:
None declared
Keywords:
Bevacizumab, elderly, safety, treatment duration
P011
RETROSPECTIVE STUDY OF FRENCH PHYSICIANS’
PRACTICES IN CAPECITABINE PRESCRIPTION FOR OLDER
PATIENTS WITH METASTATIC FIRST LINE BREAST CANCER
(CAPAGE STUDY)
D. Chauvière
1,
*, J. Viotti
2
, Y. Chateau
2
, P. Follana
3
, J.-M. Ferrero
3
,
O. Guerin
4
, E. Francois
5
, V. Mari
3
, R. Boulahssass
4
1
Clinical research,
2
Biostatistic Unit,
3
Medical oncology, Centre
Antoine Lacassagne,
4
UCOG Paca-est, CHU Nice,
5
UCOG Paca-est,
Centre Antoine Lacassagne, Nice, France
Introduction:
CAPAGE is a retrospective study of French
physicians’ practices in capecitabine prescription for old
patients (70-year-old and more) with metastatic breast cancer.
In our experience, we thought originally that older patients
received a lower capecitabine dose treatment than younger
patient (less than 70).
Objectives:
The aimof this study is to compare capecitabine
doses received by old patients compared to young patients.
We also study differences in toxicities profiles between those
two classes of age.
Methods:
We used the DPD SEIN trial database which has
included 303 patients between 2008 and 2011 in 14 sites in
France. For our study, we’ve included 291 patients : 62 patients
were in the old class of age. We compared initial dose, total
dose and dose intensity for the first three cycles between old
and young patients. We also compared toxicities.
Results:
In univariate method analysis, Age significantly
influences initial dose prescription (p 0,0001), total dose
(p=0,002) and dose-intensity (p=0,026). Total dose is also
influenced by number of nodes at diagnostic (p=0,04) and
prior endocrine therapy for metastatic disease (p=0,013). In
multivariate method analysis, Age older than 70 and high
performance status were associated with lower total dose.
Toxicity was analysed in univariated methods analysis : no
difference was. Considering only severe toxicity (grade 3-4),
nauseas (p=0,030) and vomiting (p=0,007) were higher in
older patients. Considering moderate and severe toxicities
(grade 2-4), cutaneous toxicities were higher in older patients
(p=0,0001).
Conclusion:
Our study confirms that physicians prescribe
systematically lower dose of capecitabine for patients older
than 70. Toxicity profile confirms results found in literature.
We wanted to study relation between toxicity and Arti-
Hurria predictive score but there were not enough creatinine
clearance data available. Only the ONCODAGE screening
score could be calculated in a retrospective manner : as it
was expected, no relation were found between ONCODAGE
screening score and dose or toxicity. Prospective studies are
needed to confirm our results and correlate Arti-Hurria score
with toxicities.
Disclosure of interest:
None declared
Keywords:
Capecitabine, metastatic breast cancer, practices
P012
ASTER 70S OR OPTIMAL ADJUVANT TREATMENT FOR
WOMEN OVER 70 WITH LUMINAL BREAST CANCER:
A GERICO/UNICANCER PHASE III TRIAL
F. Coussy
1
, O. Mir
2
, E. Bourbouloux
3
, S. Kirscher
4
, O. Rigal
5
,
J.-M. Ferrero
6
, D. Allouache
7
, P. Cottu
8
, G. Romieu
9
, E. Blot
10
,
A.-M. Savoye
11
, X. Durando
12
, F. Duhoux
13
, L. Venat-Bouvet
14
,
E. Malaurie
15
, C. Lefeuvre
16
, J.-L. Canon
17
, M. Lacroix-Triki
18
,
F. Rollot
19
, F. Hermitte
20
, C. Orsini
21
, C. Dubot
22
, F. Bonnetain
23
,
E. G. C. Brain
1,
*
1
Medical Oncology, Institut Curie/Hôpital René Huguenin, Saint-
Cloud,
2
Medical Oncology, Institut Gustave Roussy, Villejuif,
3
Medical Oncology, Institut de Cancérologie de l’Ouest ICO,
Nantes,
4
Instituts de cancérologie d’Avignon, Avignon,
5
Centre
Henri Becquerel, Rouen,
6
Centre Antoine-Lacassagne, Nice,
7
Centre
François Baclesse, Caen,
8
Institut Curie - Site Paris, Paris,
9
Institut